Moving toward the ideal insulin for insulin pumps (Q38631154)

4 September 2017

title

Moving toward the ideal insulin for insulin pumps (English)

1 reference

4 September 2017

1 reference

4

William V Tamborlane

1 reference

4 September 2017

1

Eda Cengiz

1 reference

4 September 2017

Bruce Bode

2

1 reference

4 September 2017

Michelle Van Name

series ordinal

3

1 reference

4 September 2017

language of work or name

1 reference

11 November 2015

1 reference

Expert Review of Medical Devices

4 September 2017

published in

1 reference

4 September 2017

volume

13

1 reference

4 September 2017

issue

1

1 reference

4 September 2017

page(s)

57-69

1 reference

Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Insulin-Pump Therapy for Type 1 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

New-generation diabetes management: glucose sensor-augmented insulin pump therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Insulin analogues: an example of applied medical science

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Continuous subcutaneous infusion of insulin lispro in children and adolescents with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Efficacy, safety, and pump compatibility of insulin aspart used in continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

A randomized trial comparing continuous subcutaneous insulin infusion of insulin aspart versus insulin lispro in children and adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

In vitro stability of insulin lispro in continuous subcutaneous insulin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Laboratory-based non-clinical comparison of occlusion rates using three rapid-acting insulin analogs in continuous subcutaneous insulin infusion catheters using low flow rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Compatibility of insulin Lispro, Aspart, and Glulisine with the Solo MicroPump, a novel miniature insulin pump

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

A web-based study of the relationship of duration of insulin pump infusion set use and fasting blood glucose level in adults with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Effect of puberty on the pharmacodynamic and pharmacokinetic properties of insulin pump therapy in youth with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Insulin glulisine: a faster onset of action compared with insulin lispro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

A novel insulin formulation with a more rapid onset of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Early pharmacokinetic and pharmacodynamic effects of mixing lispro with glargine insulin: results of glucose clamp studies in youth with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Severe hypoglycemia and diabetic ketoacidosis among youth with type 1 diabetes in the T1D Exchange clinic registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Effect of age of infusion site and type of rapid-acting analog on pharmacodynamic parameters of insulin boluses in youth with type 1 diabetes receiving insulin pump therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Use of Recombinant Human Hyaluronidase to Accelerate Rapid Insulin Analogue Absorption: Experience with Subcutaneous Injection and Continuous Infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

The alteration of aspart insulin pharmacodynamics when mixed with detemir insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Improved Pharmacokinetic and Pharmacodynamic Profile of Rapid-Acting Insulin Using Needle-Free Jet Injection Technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

A review of a family of ultra-rapid-acting insulins: formulation development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Coverage of prandial insulin requirements by means of an ultra-rapid-acting inhaled insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Technosphere insulin effectively controls postprandial glycemia in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

In silico evaluation of an artificial pancreas combining exogenous ultrafast-acting technosphere insulin with zone model predictive control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Faster pharmacokinetics and increased patient acceptance of intradermal insulin delivery using a single hollow microneedle in children and adolescents with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Clinical use of U-500 regular insulin: review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

The effect of long-term use of U-500 insulin via continuous subcutaneous infusion on durability of glycemic control and weight in obese, insulin-resistant patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Relapsing insulin-induced lipoatrophy, cured by prolonged low-dose oral prednisone: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Predicting the optimal basal insulin infusion pattern in children and adolescents on insulin pumps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Insulin doses before and one year after pump start: children have a reversed dawn phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Reduced hypoglycemia and increased time in target using closed-loop insulin delivery during nights with or without antecedent afternoon exercise in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Efficacy of Continuous Subcutaneous Insulin Infusion in Type 2 Diabetes Mellitus: A Survey on a Cohort of 102 Patients with Prolonged Follow-Up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Noninferiority effects on glycemic control and β-cell function improvement in newly diagnosed type 2 diabetes patients: basal insulin monotherapy versus continuous subcutaneous insulin infusion treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

Improved postprandial glycaemic controls with insulin Aspart in type 2 diabetic patients treated with insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586/17434440.2016.1109442

10.1586/17434440.2016.1109442

21 January 2018

Identifiers

DOI

1 reference

4 September 2017

1 reference